ArticlePloS one2026
Continuation of beta-blockers during prolonged dobutamine infusion in heart transplant-prioritised patients: A competing-risk analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients awaiting heart transplantation (HT) frequently require prolonged continuous dobutamine infusion. Whether oral beta-blocker (BB) therapy should be maintained during this period remains controversial and poorly studied, particularly in the context of prolonged concomitant use. The impact of BB continuation on waiting-list outcomes in this specific scenario is unknown.
methodsWe conducted a retrospective single-centre cohort study including adult patients listed for HT who received ≥ 30 consecutive days of concomitant oral BB therapy and continuous intravenous dobutamine between January 2020 and December 2023. The index date was defined as the first day after completion of this 30-day period, identifying patients who had already demonstrated sustained haemodynamic tolerance to the combination. Patients were classified according to BB continuation or suspension after the index date. Competing-risk analyses were performed using inverse probability of treatment weighting (IPTW), Aalen-Johansen cumulative incidence functions, and Fine-Gray regression. Robustness was assessed through nonparametric bootstrapping (1,500 replications).
resultsAmong 53 eligible patients (mean age 50.8 ± 11.9 years; 64% male), 29 underwent HT and 16 died before transplantation. After IPTW adjustment, BB continuation was associated with a higher cumulative incidence of HT at ≥ 270 days (61.1% vs 14.3%; p < 0.001) and a lower cumulative incidence of pre-transplant death (13.3% vs 68.7%; p < 0.001). Fine-Gray regression confirmed these associations: HT sHR 8.79 (95% bootstrap CI 2.66-54.31) and pre-transplant mortality sHR 0.077 (95% bootstrap CI 0.014-0.192). Results were consistent across four pre-specified sensitivity analyses.
conclusionsThis study evaluates outcomes in patients sustaining oral beta-blocker therapy during prolonged dobutamine infusion while awaiting heart transplantation, a clinical scenario with limited available data. BB continuation was associated with a higher probability of transplantation, with consistent direction across pre-specified sensitivity analyses. Given the small sample size and the potential for residual confounding by indication, these findings should be interpreted with caution and are best viewed as hypothesis-generating. They may help inform future research, particularly prospective studies in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.